Biohit Oyj B risk profile
28 Normal where most of the sector sits
Measured 21 October 2026 from BIOBV's filed statements. Recomputed nightly.
28 (Normal), driven by Cash conversion at 98, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 70 | Stretched | Volatile | Drawdown from the 52-week high — 41.4% |
| Operating pressure | 28 | Normal | Worsening | Costs outgrowing revenue — -2.0 percentage points |
| Cash conversion | 98 | Acute | Worsening | Capital spending against operating cash — -0.83x |
| Leverage and coverage | 5 | Contained | Stable | Current ratio — 2.56x |
| Competitive position | 9 | Contained | Stable | Revenue-growth gap against peers — +33.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.